Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumanta Kumar Pal

Showing results (11-20 of 94) with videos related to

Pageof 10
Sort By:
Clinical Genitourinary Cancer|August 6, 2011
Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXISSumanta Kumar Pal, Nicholas J Vogelzang
The Journal of Urology|February 15, 2019
Editorial CommentNicholas James Salgia, Sumanta Kumar Pal
Clinical Advances in Hematology & Oncology : H&O|April 20, 2013
Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinomaSumanta Kumar Pal, Nicholas J Vogelzang
Nature Reviews. Clinical Oncology|July 2, 2010
Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscapeSumanta Kumar Pal, Robert A Figlin
Seminars in Oncology|August 5, 2010
Safety considerations for use of bone-targeted agents in patients with cancerJoanne E Mortimer, Sumanta Kumar Pal
Clinical Advances in Hematology & Oncology : H&O|April 20, 2010
Renal cell carcinoma therapy in 2010: many options with little comparative dataSumanta Kumar Pal, Robert A Figlin
Expert Opinion on Biological Therapy|October 20, 2010
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small moleculesSumanta Kumar Pal, Robert A Figlin
Cancer Discovery|May 16, 2012
Unraveling the role of hypoxia-inducible factor in renal cell carcinoma: a biological and therapeutic perspectiveSumanta Kumar Pal, Robert A Figlin
Clinical Genitourinary Cancer|January 2, 2013
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for positionSumanta Kumar Pal, Nicholas J Vogelzang
Targeted Oncology|April 13, 2011
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinomaSumanta Kumar Pal, Robert A Figlin
Pageof 10

Showing results (11-20 of 94) with videos related to

Sort By:
Pageof 10
Clinical Genitourinary Cancer|August 6, 2011
Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXISSumanta Kumar Pal, Nicholas J Vogelzang
The Journal of Urology|February 15, 2019
Editorial CommentNicholas James Salgia, Sumanta Kumar Pal
Clinical Advances in Hematology & Oncology : H&O|April 20, 2013
Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinomaSumanta Kumar Pal, Nicholas J Vogelzang
Nature Reviews. Clinical Oncology|July 2, 2010
Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscapeSumanta Kumar Pal, Robert A Figlin
Seminars in Oncology|August 5, 2010
Safety considerations for use of bone-targeted agents in patients with cancerJoanne E Mortimer, Sumanta Kumar Pal
Clinical Advances in Hematology & Oncology : H&O|April 20, 2010
Renal cell carcinoma therapy in 2010: many options with little comparative dataSumanta Kumar Pal, Robert A Figlin
Expert Opinion on Biological Therapy|October 20, 2010
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small moleculesSumanta Kumar Pal, Robert A Figlin
Cancer Discovery|May 16, 2012
Unraveling the role of hypoxia-inducible factor in renal cell carcinoma: a biological and therapeutic perspectiveSumanta Kumar Pal, Robert A Figlin
Clinical Genitourinary Cancer|January 2, 2013
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for positionSumanta Kumar Pal, Nicholas J Vogelzang
Targeted Oncology|April 13, 2011
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinomaSumanta Kumar Pal, Robert A Figlin
Pageof 10